Barclays PLC Grows Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Barclays PLC raised its stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 234.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 156,857 shares of the company's stock after acquiring an additional 109,923 shares during the period. Barclays PLC owned about 0.30% of PROCEPT BioRobotics worth $12,631,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Lord Abbett & CO. LLC increased its holdings in PROCEPT BioRobotics by 45.3% in the 3rd quarter. Lord Abbett & CO. LLC now owns 748,555 shares of the company's stock worth $59,974,000 after acquiring an additional 233,430 shares during the last quarter. Perpetual Ltd bought a new position in PROCEPT BioRobotics in the 4th quarter worth approximately $66,972,000. Oak Ridge Investments LLC raised its holdings in PROCEPT BioRobotics by 24.0% during the 4th quarter. Oak Ridge Investments LLC now owns 30,059 shares of the company's stock valued at $2,420,000 after acquiring an additional 5,817 shares during the period. SG Americas Securities LLC lifted its position in shares of PROCEPT BioRobotics by 295.8% during the fourth quarter. SG Americas Securities LLC now owns 6,598 shares of the company's stock worth $531,000 after acquiring an additional 4,931 shares in the last quarter. Finally, Chicago Capital LLC grew its position in shares of PROCEPT BioRobotics by 44.5% in the fourth quarter. Chicago Capital LLC now owns 379,582 shares of the company's stock valued at $30,564,000 after purchasing an additional 116,931 shares in the last quarter. Hedge funds and other institutional investors own 89.46% of the company's stock.

Insider Activity at PROCEPT BioRobotics

In related news, CEO Reza Zadno sold 5,475 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $312,403.50. Following the completion of the transaction, the chief executive officer now owns 173,070 shares in the company, valued at $9,875,374.20. This represents a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Kevin Waters sold 733 shares of the firm's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the sale, the chief financial officer now directly owns 107,991 shares of the company's stock, valued at $6,161,966.46. The trade was a 0.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,455 shares of company stock worth $368,322 in the last three months. 17.40% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have commented on PRCT shares. Morgan Stanley cut their target price on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Truist Financial lowered their target price on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, April 11th. Finally, Bank of America decreased their price target on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a report on Friday. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $90.00.

PROCEPT BioRobotics Trading Down 0.1 %

Shares of PROCEPT BioRobotics stock traded down $0.07 during trading on Friday, reaching $52.49. The company's stock had a trading volume of 1,973,062 shares, compared to its average volume of 809,071. The company has a market cap of $2.88 billion, a price-to-earnings ratio of -26.92 and a beta of 1.09. The firm's 50-day moving average is $57.74 and its two-hundred day moving average is $73.98. PROCEPT BioRobotics Co. has a 52-week low of $47.04 and a 52-week high of $103.81. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.04. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The company had revenue of $69.16 million during the quarter, compared to analyst estimates of $65.39 million. On average, sell-side analysts anticipate that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).